BioMarin sells Priority Review voucher for $125M

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) agreed to sell its rare pediatric disease Priority Review voucher for $125 million to an undisclosed buyer. BioMarin received the voucher in April when FDA approved Brineura cerliponase alfa to treat late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease (see BioCentury, April 28)...